RealTime Dynamix™: Psoriasis US Q2 2016 Spotlight


RealTime Dynamix™: Psoriasis Q2

RealTime Dynamix™: Psoriasis Q2 is the first report in a three-part 2016 series focusing on current and anticipated future trends in the PsO market. Report content also includes a detailed look at dermatologists’ adoption of Taltz. Major inline brands covered include Cosentyx, Enbrel, Humira, Otezla, Remicade, Stelara, and Taltz. PsO pipeline agents covered include brodalumab, guselkumab, tildrakizumab, and the recently approved biosimilar, Inflectra. Here we spotlight some key findings from this robust study.

US dermatologistsare reporting early adoption of the most recent addition to the psoriasis armamentarium, Eli Lilly’s Taltz (ixekizumab).

Though historically, the TNF-inhibitors have been the most commonly used biologics for psoriasis management, agents with new mechanisms of action are carving their niche as viable treatment options. Indeed, the IL-17 inhibitors, Taltz and Cosentyx, capture 10% of biologic market share in PsO.

Brand Share Among Biologic
Treated PSO Patients



33% of surveyed dermatologists have already trialed Taltz at just over one month post launch.


In contrast, 66% of respondents currently use Cosentyx, the only other currently approved IL-17 inhibitor for PsO, which has been available for 18 months.

Profile of a Taltz Patient

28% were switched from either cosentyx, Stelara or Otezla.

73% have serve psoriasis

43% were required to provide proof of 1 TNF failure for managed care approval.


26% of initiations were primarily attributed to the effectiveness of taltz.

39% were switched from a TNF inhibitor

53% are on Taltz monotherapy

Moving forward, more than 95% of the survey respondents anticipate using Taltz in their practice.
Current users expecttheir use of Taltz to more than triple in the next three months, while during
the same time frame more than 20% of non-users expect to initiate trial.
For current non-users, when do you
anticipate you will prescribe Taltz
for your PsO patients?

RealTime Dynamix: Psoriasis is a quarterly report that allows for close-quarters monitoring of key performance metrics and provides a detailed and timely look at current trends in the PsO market. For more information contact: [email protected]